A Phase 3 Study of Micafungin Versus Amphotericin B Deoxycholate in Infants With Invasive Candidiasis

Daniel K Benjamin Jr, David A Kaufman, William W Hope, P Brian Smith, Antonio Arrieta, Paolo Manzoni, Laura L Kovanda, Christopher Lademacher, Brigit Isaacson, Deborah Jednachowski, Chunzhang Wu, Atsunori Kaibara, Thomas J Walsh, Daniel K Benjamin Jr, David A Kaufman, William W Hope, P Brian Smith, Antonio Arrieta, Paolo Manzoni, Laura L Kovanda, Christopher Lademacher, Brigit Isaacson, Deborah Jednachowski, Chunzhang Wu, Atsunori Kaibara, Thomas J Walsh

Abstract

Background: Amphotericin B deoxycholate (AmB-D) is standard of care treatment for neonatal invasive candidiasis (IC). Micafungin (MCA) has broad-spectrum fungicidal activity against Candida spp. We compared the efficacy and safety of intravenous MCA with intravenous AmB-D and assessed the pharmacokinetics of MCA in infants >2-120 days of age with proven IC in a phase 3, randomized, double-blind, multicenter, parallel-group, noninferiority study (NCT00815516).

Methods: Infants were randomized 2:1 to MCA (10 mg/kg/d) or AmB-D (1 mg/kg/d) for ≥21 days. Primary efficacy endpoint was fungal-free survival (FFS) 1 week after last study drug dose. MCA population pharmacokinetics included simulated area under the curve (AUC) at steady state and maximum plasma concentration after 2-hour infusion. AUC pharmacodynamic target exposure was 170 µg·h/mL.

Results: Thirty infants received MCA (n = 20) or AmB-D (n = 10). The trial was terminated early because of slow recruitment. FFS was observed in 12 of 20 [60%; 95% confidence interval (CI): 36%-81%] MCA-group infants and in 7 of 10 (70%; 95% CI: 35%-93%) AmB-D-group infants. The most common treatment-emergent adverse events were anemia [MCA: n = 9 (45%); AmB-D: n = 3 (30%)] and thrombocytopenia [n = 2 (10%) and n = 3 (30%), respectively]. Model-derived mean AUC at steady state for MCA was 399.3 ± 163.9 µg·h/mL (95% prediction interval: 190.3-742.3 µg/mL); steady state and maximum plasma concentration after 2-hour infusion was 31.1 ± 10.5 µg/mL (95% prediction interval: 17.0-49.7 µg/mL). MCA exposures were above the AUC pharmacodynamic target exposure.

Conclusions: Within the study limitations, infants with IC treated with MCA achieved similar FFS compared with AmB-D. Both agents were safe and well tolerated.

References

    1. Barton M, O’Brien K, Robinson JL, et al. Invasive candidiasis in low birth weight preterm infants: risk factors, clinical course and outcome in a prospective multicenter study of cases and their matched controls. BMC Infect Dis. 2014;14:327.
    1. Ascher SB, Smith PB, Watt K, et al. Antifungal therapy and outcomes in infants with invasive Candida infections. Pediatr Infect Dis J. 2012;31:439–443..
    1. Benjamin DK, Jr, Poole C, Steinbach WJ, et al. Neonatal candidemia and end-organ damage: a critical appraisal of the literature using meta-analytic techniques. Pediatrics. 2003;112(3, pt 1):634–640..
    1. Adams-Chapman I, Bann CM, Das A, et al. Eunice Kennedy Shriver National Institutes of Child Health and Human Development Neonatal Research Network. Neurodevelopmental outcome of extremely low birth weight infants with Candida infection. J Pediatr. 2013;163:961–967.e963..
    1. Chapman RL, Faix RG.Persistently positive cultures and outcome in invasive neonatal candidiasis. Pediatr Infect Dis J. 2000;19:822–827..
    1. Hope WW, Castagnola E, Groll AH, et al. ESCMID Fungal Infection Study Group. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp. Clin Microbiol Infect. 2012;18suppl 7:38–52..
    1. Pappas PG, Kauffman CA, Andes DR, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62:e1–e50..
    1. Botero-Calderon L, Benjamin DK, Jr, Cohen-Wolkowiez M.Advances in the treatment of invasive neonatal candidiasis. Expert Opin Pharmacother. 2015;16:1035–1048..
    1. Manzoni P, Mostert M, Castagnola E.Update on the management of Candida infections in preterm neonates. Arch Dis Child Fetal Neonatal Ed. 2015;100:F454–459..
    1. Bes DF, Rosanova MT, Sberna N, et al. Deoxycholate amphotericin B and nephrotoxicity in the pediatric setting. Pediatr Infect Dis J. 2014;33:e198–e206..
    1. Almirante B, Rodríguez D.Antifungal agents in neonates: issues and recommendations. Paediatr Drugs. 2007;9:311–321..
    1. Autmizguine J, Guptill JT, Cohen-Wolkowiez M, et al. Pharmacokinetics and pharmacodynamics of antifungals in children: clinical implications. Drugs. 2014;74:891–909..
    1. Kazak E, Akin H, Ener B, et al. An investigation of Candida species isolated from blood cultures during 17 years in a university hospital. Mycoses. 2014;57:623–629..
    1. Wade KC, Benjamin DK, Jr, Kaufman DA, et al. Fluconazole dosing for the prevention or treatment of invasive candidiasis in young infants. Pediatr Infect Dis J. 2009;28:717–723..
    1. Zarei Mahmoudabadi A, Rezaei-Matehkolaei A, Navid M, et al. Colonization and antifungals susceptibility patterns of Candida species isolated from hospitalized patients in ICUs and NICUs. J Nephropathol. 2015;4:77–84..
    1. Caudle KE, Inger AG, Butler DR, et al. Echinocandin use in the neonatal intensive care unit. Ann Pharmacother. 2012;46:108–116..
    1. Manzoni P, Benjamin DK, Hope W, et al. The management of Candida infections in preterm neonates and the role of micafungin. J Matern Fetal Neonatal Med. 2011;24suppl 2:24–27..
    1. Hope WW, Mickiene D, Petraitis V, et al. The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: implications for echinocandin therapy in neonates. J Infect Dis. 2008;197:163–171..
    1. Hope WW, Smith PB, Arrieta A, et al. Population pharmacokinetics of micafungin in neonates and young infants. Antimicrob Agents Chemother. 2010;54:2633–2637..
    1. Benjamin DK, Jr, Smith PB, Arrieta A, et al. Safety and pharmacokinetics of repeat-dose micafungin in young infants. Clin Pharmacol Ther. 2010;87:93–99..
    1. Astellas Pharma Europe B.V. Mycamine: EPAR product information. Available at: . Accessed September 29, 2015.
    1. Astellas Pharma US I. MYCAMINE® (micafungin) prescribing information. Available at: . Accessed September 29, 2015.
    1. Pappas PG, Kauffman CA, Andes D, et al. Infectious Diseases Society of America. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;48:503–535..
    1. Rodriguez-Tudela JL, Arendrup MC, Barchiesi F, et al. EUCAST definitive document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. Clin Microbiol Infect. 2008;14:398–405..
    1. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts. M27-A3. 2008Wayne, PA: Clinical and Laboratory Standards Institute;
    1. Hope WW, Kaibara A, Roy M, et al. Population pharmacokinetics of micafungin and its metabolites M1 and M5 in children and adolescents. Antimicrob Agents Chemother. 2015;59:905–913..
    1. Heresi GP, Gerstmann DR, Reed MD, et al. The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants. Pediatr Infect Dis J. 2006;25:1110–1115..
    1. Undre NA, Stevenson P, Freire A, et al. Pharmacokinetics of micafungin in pediatric patients with invasive candidiasis and candidemia. Pediatr Infect Dis J. 2012;31:630–632..
    1. Kaufman D, Boyle R, Hazen KC, et al. Fluconazole prophylaxis against fungal colonization and infection in preterm infants. N Engl J Med. 2001;345:1660–1666..
    1. Clerihew L, Lamagni TL, Brocklehurst P, et al. Candida parapsilosis infection in very low birthweight infants. Arch Dis Child Fetal Neonatal Ed. 2007;92:F127–129..
    1. Garzillo C, Bagattini M, Bogdanović L, et al. Risk factors for Candida parapsilosis bloodstream infection in a neonatal intensive care unit: a case-control study. Ital J Pediatr. 2017;43:10.
    1. Steinbach WJ, Roilides E, Berman D, et al. International Pediatric Fungal Network. Results from a prospective, international, epidemiologic study of invasive candidiasis in children and neonates. Pediatr Infect Dis J. 2012;31:1252–1257..
    1. Viscoli C, Bassetti M, Castagnola E, et al. Micafungin for the treatment of proven and suspected invasive candidiasis in children and adults: findings from a multicenter prospective observational study. BMC Infect Dis. 2014;14:725.
    1. Queiroz-Telles F, Berezin E, Leverger G, et al. Micafungin Invasive Candidiasis Study Group. Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial. Pediatr Infect Dis J. 2008;27:820–826..
    1. Benjamin DK, Jr, Driscoll T, Seibel NL, et al. Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections. Antimicrob Agents Chemother. 2006;50:632–638..
    1. Lutsar I, Metsvaht T.Understanding pharmacokinetics/pharmacodynamics in managing neonatal sepsis. Curr Opin Infect Dis. 2010;23:201–207..
    1. Le J, Adler-Shohet FC, Nguyen C, et al. Nephrotoxicity associated with amphotericin B deoxycholate in neonates. Pediatr Infect Dis J. 2009;28:1061–1063..
    1. Loo AS, Muhsin SA, Walsh TJ.Toxicokinetic and mechanistic basis for the safety and tolerability of liposomal amphotericin B. Expert Opin Drug Saf. 2013;12:881–895..
    1. Fanos V, Cataldi L.Amphotericin B-induced nephrotoxicity: a review. J Chemother. 2000;12:463–470..
    1. Manzoni P, Wu C, Tweddle L, et al. Micafungin in premature and non-premature infants: a systematic review of 9 clinical trials. Pediatr Infect Dis J. 2014;33:e291–e298..
    1. Groll AH, Mickiene D, Petraitiene R, et al. Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling. Antimicrob Agents Chemother. 2001;45:2845–2855..
    1. Petraitis V, Petraitiene R, Groll AH, et al. Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother. 2002;46:1857–1869..
    1. Odio CM, Araya R, Pinto LE, et al. Caspofungin therapy of neonates with invasive candidiasis. Pediatr Infect Dis J. 2004;23:1093–1097..
    1. Gabardi S, Martin S, Sura M, et al. Micafungin treatment and eradication of candiduria among hospitalized patients. Int Urol Nephrol. 2016;48:1881–1885..
    1. Grau S, Luque S, Echeverría-Esnal D, et al. Urinary micafungin levels are sufficient to treat urinary tract infections caused by Candida spp. Int J Antimicrob Agents. 2016;48:212–214..
    1. Aliaga S, Clark RH, Laughon M, et al. Changes in the incidence of candidiasis in neonatal intensive care units. Pediatrics. 2014;133:236–242..
    1. Turkova A, Roilides E, Sharland M.Amphotericin B in neonates: deoxycholate or lipid formulation as first-line therapy - is there a ‘right’ choice? Curr Opin Infect Dis. 2011;24:163–171..

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever